-
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trialYi Li, QM Jing, YL Han et al. -
Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI)Orme RC, Parker WAE, Storey RF et al.
-
Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting StentAJ Kirtane, R Stoler, R Feldman et al.
-
Ticagrelor with or without Aspirin in High-Risk Patients after PCIR Mehran, U Baber, SK Sharma et al.
-
Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery diseaseM Bossard, P Gao, W Boden et al.
-
Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled TrialK Kanenawa, K Yamaji, H Tashiro et al.
-
Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapyvan Rein N, Heide-Jørgensen U, Lijfering WM et al.
-
A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trialWJ Jang, JB Lee, YB Song et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
